Melanotan-1 research focuses on melanocortin receptor pharmacology, melanocyte biology, melanin synthesis and cellular responses to ultraviolet-related signalling, with MC1R structure and regulation reviewed extensively in the literature (Learn more). Experimental models examine how alpha-MSH analogues activate MC1R and influence downstream cyclic-AMP pathways involved in pigmentation biology, alongside related melanocortin research such as Melanotan-2 and PT-141.
From frog skin to a superpotent probe: the Arizona origins
Melanotan-1 began with a puzzle at the University of Arizona. Chemist Victor Hruby and physiologist Mac Hadley noticed that alpha-MSH briefly heated in alkali went on darkening frog skin for far longer than the untreated hormone. Gas chromatography of the treated peptide explained why: the heat-alkali step had partly converted two residues, methionine at position 4 and phenylalanine at position 7, into altered forms. Instead of working with an unpredictable mixture, the team designed those changes in on purpose.
The result, reported by Sawyer and colleagues in PNAS in 1980, was [Nle4, D-Phe7]-alpha-MSH, the molecule sold today as Melanotan-1. It shrugged off serum enzymes, was 26 times as potent as alpha-MSH at switching on adenylate cyclase in mouse melanoma cells, and raised tyrosinase activity in the same cells. A follow-up paper in Science described frog skins that stayed dark for at least six weeks after a single treatment with the analogue, compared with a few days for the natural hormone. The authors predicted it would become an important probe for melanotropin receptors, and so it proved.
Norleucine and D-phenylalanine: two swaps, one sturdier hormone
Natural alpha-MSH reads Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. Melanotan-1 keeps eleven of those thirteen residues exactly, along with the acetyl cap at the front and the amide at the tail. Only two positions change.
At position 4, methionine gives way to norleucine. The two side chains are almost the same length, but methionine carries a sulphur atom that oxidises readily, while norleucine is a plain hydrocarbon chain. At position 7, ordinary L-phenylalanine is replaced by its mirror image, D-phenylalanine. This residue sits inside His-Phe-Arg-Trp, the four-residue core that every melanocortin peptide uses to engage its receptors, and the D-form is thought to help the backbone fold into a turn that the receptor recognises more readily. The combined result is higher potency and slower breakdown, which is why Melanotan-1 became a reference agonist.
Beyond pigment: MC1R and the UV damage response
MC1R is best known as the switch for eumelanin production, but cell research has shown that it does more than colour. Zalfa Abdel-Malek’s group at the University of Cincinnati found that in cultured human melanocytes, alpha-MSH acting through MC1R reduced DNA photoproducts and oxidative stress after ultraviolet exposure and helped the cells survive UV-induced apoptosis. Later work showed the hormone raising levels of XPC, the protein that recognises damaged DNA, and boosting signalling through the damage sensors ATR and ATM.
The striking control in these experiments was genetic. Melanocytes carrying loss-of-function MC1R variants did not show the protective responses, tying them firmly to the receptor itself. The same group has since built small analogues around the His-D-Phe-Arg core to probe this repair pathway. For researchers, that makes potent MC1R agonists useful tools for questions about genomic stability in pigment cells as well as for classic melanogenesis assays.
Afamelanotide: the licensed medicine with this sequence
The sequence of Melanotan-1 also carries an international nonproprietary name, afamelanotide, and in that form it reached the clinic. The Australian company Clinuvel developed afamelanotide as a 16mg controlled-release implant under the brand name Scenesse, for erythropoietic protoporphyria (EPP). EPP is an inherited disorder in which protoporphyrin IX accumulates and triggers painful phototoxic reactions when skin is exposed to light.
Two randomised, placebo-controlled trials, one in Europe with 74 participants and one in the United States with 94, were published in the New England Journal of Medicine in 2015. The European Medicines Agency authorised Scenesse on 22 December 2014, under exceptional circumstances, for the prevention of phototoxicity in adults with EPP. The US FDA followed on 8 October 2019, approving it to increase pain-free light exposure in adults with a history of phototoxic reactions from EPP, the first FDA-approved treatment for the condition. Crown Peptides Melanotan-1 is a freeze-dried research peptide with the same amino-acid sequence; it is not Scenesse, which is a formulated, licensed implant.
